Welcome to our dedicated page for BioRestorative Therapies news (Ticker: BRTX), a resource for investors and traders seeking the latest updates and insights on BioRestorative Therapies stock.
BioRestorative Therapies, Inc. (NASDAQ: BRTX) is a cutting-edge biotechnology company based in the United States, dedicated to developing regenerative medicine products and therapies using cell and tissue protocols, particularly involving adult stem cells. The company’s core focuses are its Disc/Spine Program and Metabolic Program.
In the Disc/Spine Program, their lead cell therapy candidate, BRTX-100, is formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow. This innovative treatment is designed for the non-surgical management of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. BRTX-100 undergoes a meticulous production process, starting from the collection of a patient’s bone marrow, followed by the isolation and culturing of stem cells, and finally cryopreserving these cells. The therapy involves injecting BRTX-100 into the patient's damaged disc, offering hope for patients whose pain has not been alleviated by other non-invasive treatments.
The Metabolic Program focuses on developing cell-based therapies to combat obesity and metabolic disorders using brown adipose-derived stem cells. This innovative approach aims to generate brown adipose tissue to help address these widespread health issues.
BioRestorative Therapies is also venturing into the rapidly growing bio-cosmeceutical market. The company recently signed a five-year exclusive supply agreement with Cartessa Aesthetics, LLC, a prominent North American aesthetics company. This partnership aims to introduce proprietary cell-based innovations to the aesthetics market, leveraging both BioRestorative’s expertise in cell-based biologics and Cartessa’s strong market presence.
Financially, BioRestorative is strong, ending 2023 with around $11.1 million in cash and cash equivalents, and an additional $7.6 million from a recent private placement. This solid financial standing, combined with expected revenues from its new commercial products, allows the company to pursue further advancements in their clinical and preclinical pipelines, including their BRTX-100 and ThermoStem® programs.
For more information, visit BioRestorative Therapies or contact Investor Relations at ir@biorestorative.com.
BioRestorative Therapies, Inc. (Nasdaq: BRTX) has announced its participation in the RHK Capital Disruptive Growth Conference scheduled for December 5-6, 2022, in New York City. Lance Alstodt, the company's President and CEO, will engage in one-on-one meetings to discuss the latest updates on the company's expanded pipeline and ongoing Phase 2 clinical trial targeting chronic lumbar disc disease. The trial utilizes the BRTX-100 cell therapy, which aims to provide non-surgical treatment for painful lumbosacral disc disorders.
BioRestorative Therapies (NASDAQ: BRTX) announced an upcoming interview with CEO Lance Alstodt on Famela and Friends Talk Radio, focusing on the company's clinical development pipeline. BioRestorative is currently conducting a Phase 2 trial for its lead therapy candidate, BRTX-100, aimed at treating chronic lumbar disc disease. The trial involves up to 99 patients across 15 U.S. centers, assessing safety and efficacy. The company also highlighted its Metabolic Program utilizing stem cells from brown adipose tissue.
BioRestorative Therapies (NASDAQ: BRTX) announced CEO Lance Alstodt will present at the Dawson James Securities 7th Annual Small Cap Growth Conference on October 12, 2022, in Jupiter, Florida. The presentation will cover the company's Phase 2 clinical trial using BRTX-100, aimed at treating chronic lumbar disc disease. This double-blind trial will involve up to 99 patients at 15 sites in the U.S., comparing the investigational drug to a control group.
For live webcasts and details, visit BioRestorative's website.
BioRestorative Therapies (NASDAQ: BRTX) announced that CEO Lance Alstodt will speak at the Roth Inaugural Healthcare Opportunities Conference on October 6, 2022, in New York City. He will provide updates on the Phase 2 clinical trial of BRTX-100, a stem cell therapy aimed at treating chronic lumbar disc disease. The trial involves up to 99 patients across 15 sites, comparing the investigational treatment against a control.
Meetings with management can be arranged through Roth representatives.
BioRestorative Therapies (BRTX) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. CEO Lance Alstodt will provide updates on the company's expanded pipeline, specifically the Phase 2 clinical trial targeting chronic lumbar disc disease. The presentation is scheduled for September 14, 2022, at 11:30 AM EDT. BioRestorative focuses on cell-based therapies for disc disorders and metabolic conditions, including its lead candidate BRTX-100, aimed at non-surgical treatment for lower back pain.
BioRestorative Therapies (NASDAQ: BRTX) has achieved a significant milestone by enrolling the first patient in its Phase 2 clinical trial for BRTX-100, aimed at addressing chronic lumbar disc disease (cLDD). This double-blind, controlled study will involve up to 99 patients across 15 U.S. sites. CEO Lance Alstodt emphasized the importance of this enrollment, highlighting a commitment to advancing treatment options for back pain and ensuring timely execution of their clinical programs. The trial may represent a paradigm shift in the treatment of chronic back pain.
BioRestorative Therapies (NASDAQ: BRTX) has secured a second clinical site for its Phase 2 trial targeting chronic lumbar disc disease (cLDD). This trial will evaluate the safety and preliminary efficacy of BRTX-100, an autologous stem cell-based therapy, through a randomized double-blind study involving up to 99 patients across 15 sites in the U.S. The principal investigator, Dr. Richard Rauck, will lead the trial at the Center for Clinical Research in North Carolina, enhancing the clinical expertise essential for the trial's success.
BioRestorative Therapies (NASDAQ: BRTX) has initiated site preparation for its Phase 2 clinical trial targeting chronic lumbar disc disease (cLDD). The Denver Spine and Pain Institute is the first site ready to enroll patients. The trial will assess the safety and preliminary efficacy of a single intradiscal injection of the investigational stem cell therapy BRTX-100, involving up to 99 patients across 15 centers in a randomized, controlled study. There are currently no approved cell-based therapies for cLDD, and positive trial outcomes could disrupt existing treatment paradigms.
BioRestorative Therapies (NASDAQ: BRTX) announced a Principal Investigators Meeting on April 29-30, 2022, in Uniondale, NY, for their lead clinical candidate BRTX-100 aimed at treating chronic lumbar disc disease. This Phase 2 trial plans to recruit 99 subjects across 15 clinical sites in the U.S. The company aims to coordinate study goals among principal investigators to ensure best practices. Low back pain affects 80% of adults in the U.S., representing a significant healthcare burden.
BioRestorative Therapies (NASDAQ: BRTX) has chosen 10 clinical sites for its Phase 2 trial targeting chronic lumbar disc disease. This double-blind, randomized study aims to evaluate the safety and preliminary efficacy of the investigational drug BRTX-100 through a single intradiscal injection. A total of up to 99 eligible patients will be randomized across 15 centers. The selection of high-caliber clinics is highlighted as a significant milestone, indicating BioRestorative's commitment to enhancing treatment options for patients suffering from this condition.
FAQ
What is the current stock price of BioRestorative Therapies (BRTX)?
What is the market cap of BioRestorative Therapies (BRTX)?
What does BioRestorative Therapies, Inc. specialize in?
What are the main programs developed by BioRestorative Therapies?
What is BRTX-100?
How does BRTX-100 work?
What recent partnership has BioRestorative Therapies entered into?
How financially stable is BioRestorative Therapies?
What are the potential benefits of the partnership with Cartessa Aesthetics?
What is the focus of BioRestorative's Metabolic Program?
Who can I contact for investor relations at BioRestorative Therapies?
Where can I find more information about BioRestorative Therapies?
